May 25, 2023 BioIntegrates 2023: Biotech pinch points and strategic decisions By Ellen Lambrix Ellen Lambrix and Adam Coughlin from Bristows' Commercial IP team attended the BioIntegrates conference in London on 16 May 2023. With...
Mar 27, 2023 Cell and gene therapy platforms licensing – exclusivity and carving-up fields By Louisa Jacobs Cell and gene therapies (CGTs) are highly complex and sophisticated technologies with a lot of constituent parts. To bring a product to...
Mar 01, 2023 Consultation on the Reform of the Human Fertilisation & Embryology Act Regulating Scientific Advance By Julian Hitchcock This HFEA consultation, launched on Tuesday, is important not only for IVF clinics, but to all those working in the fields of...
Feb 22, 2023 Techbio: sourcing, valuing and sharing data in an AI world – takeaways from Genesis 2022 By Claire Smith The life sciences industry saw unprecedented levels of activity in 2020 and 2021 in the fight against Covid. In 2022 we saw a different...
Feb 20, 2023 Platform technology collaborations – who owns the arising IP? By Louisa Jacobs Claire Smith Platform technologies, often the core business of a biotech or techbio company, can be extremely valuable assets. Whether it’s a high...
Feb 16, 2023 The Other Big C: Thanks to the rapid development of the Covid vaccines - could we see cancer vaccines available to patients by the end of the decade? By Alexandra Harmer At the start of this year, BioNTech announced a strategic partnership with the UK government to provide up to 10,000 patients with...
Feb 15, 2023 Libmeldy®, an autologous gene therapy, has been used for the first time on the NHS By Aida Tohala Libmeldy® is a treatment for early-onset metachromatic leukodystrophy (MLD), a rare, inherited and otherwise fatal disease that causes...
Jan 23, 2023 Cell and gene therapies - licensing considerations By Louisa Jacobs Last month, Atara Biotherapeutics’ Ebvallo was granted marketing authorisation in the EU - the first off-the-shelf T-cell immunotherapy...
Nov 21, 2022 The convergence of One Medicine and advanced therapeutics By Erik Müürsepp Which is more sensible, sacrificing hundreds of laboratory mice during the development of a therapeutic or using highly advanced model...
Nov 18, 2022 A gene therapy for haemophilia – from the lab to the patient By Louisa Jacobs UCLB, the commercialisation company of UCL, held a Winter Showcase event on 16 November 2022 to highlight some of their recent successes...
Nov 16, 2022 The industry perspective on cell & gene therapies and vaccines manufacturing By Ellen Lambrix Cell and gene therapies (CGTs) are transforming the way we treat, and even cure, disease. Since the first CAR-T therapy was approved in...
Oct 21, 2022 The birth of techbio - but what does techbio want to be when it grows up? By Claire Smith BIA’s TechBio UK Event Bristows had the pleasure of attending TechBio UK 2022 on 13 October. It was a fantastic event held by the...